[go: up one dir, main page]

ES2138594T3 - Agentes derivados de piridina e imidazol para enfermedades cardiovasculares. - Google Patents

Agentes derivados de piridina e imidazol para enfermedades cardiovasculares.

Info

Publication number
ES2138594T3
ES2138594T3 ES92906439T ES92906439T ES2138594T3 ES 2138594 T3 ES2138594 T3 ES 2138594T3 ES 92906439 T ES92906439 T ES 92906439T ES 92906439 T ES92906439 T ES 92906439T ES 2138594 T3 ES2138594 T3 ES 2138594T3
Authority
ES
Spain
Prior art keywords
alkyl
pct
thromboxane
optionally
chch3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906439T
Other languages
English (en)
Inventor
Roger Peter Dickinson
Kevin Neil Dack
John Steele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2138594T3 publication Critical patent/ES2138594T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Treating Waste Gases (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

SE DESCRIBEN LOS COMPUESTOS DE FORMULA (I) O UN ESTER BIOCALIFICABLE DE LOS MISMOS, UNA SAL FARMACEUTICAMENTE ACEPTABLE O AMBOS, EN DONDE R1,R2,R3 Y R4 SON CADA UNO SELECCIONADOS INDEPENDIENTEMENTE DE H O ALQUILO C1-C4; R5 ES (CH2)MSO2R6, (CH2)MNHSO2R6 O (CH2)NHCOR7; R6 Y R7 SON ALQUILO C1-C6, PERFLUOROALQUILO(CH2)N C1-C3, CICLOALQIL(CH2)N C3-C6, ARIL(CH2)N O HETEROARIL(CH2)N; O R6 E NR8R9; R8 ES H O ALQUILO C1-C4; R9 ES ALQUILO C1-C6, CICLOALQUIL(CH2)N C3-C6, ARIL(CH2)N O HETEROARIL(CH2); O R8 Y R9 JUNTOS CON EL ATOMO DE NITROGENO AL CUAL ESTAN ADJUNTOS FORMAN UN ANILLO HETEROCICLICO DE 5 A 7 MIEMBROS QUE PUEDE OPCIONALMENTE INCORPORAR UN DOBLE ENLACE CARBON-CARBON O UNA UNION ATOMICA SELECCIONADA DE O, S, NH, N(ALQUIL C1-C4) Y N(ALCANOIL C1C5), Y QUE PUEDE SER OPCIONALMENTE SUSTITUIDO CON UNO DE TRES SUSTITUYENTES INDEPENDIENTEMENTE SELECCIONADOS DE ALQUILO C2-C4 Y ALCOXI C1-C4, QUE PUEDEN OPCIONALMENTE SER BENZO-FISIONADOS; X E CH2, CHCH3, C(OH)CH3, C=CH2 U O; M ES 0 O 1; N ES 0, 1, 2 O3; Y HET ES PIRIMIDIL 3CON LA PREVISION DE CUANDO HET ES IMIDAZILIL-1 ENTONCES X ES CH2 O CHCH3.LOS COMPUESTOS SON INHIBIDORES DE SINTETASA A2 TROMOXANA COMBINADA Y ANTAGONISTAS DE ENDOPEROXIDO/A2 TROMBOXANA DE UTILIDAD EN EL TRATAMIENTO DE ENFERMEDADES EN LAS CUALES LA TOMBOXANA A2 ES UN AGENTE CAUSATIVO.
ES92906439T 1991-04-04 1992-03-17 Agentes derivados de piridina e imidazol para enfermedades cardiovasculares. Expired - Lifetime ES2138594T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919107043A GB9107043D0 (en) 1991-04-04 1991-04-04 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2138594T3 true ES2138594T3 (es) 2000-01-16

Family

ID=10692617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906439T Expired - Lifetime ES2138594T3 (es) 1991-04-04 1992-03-17 Agentes derivados de piridina e imidazol para enfermedades cardiovasculares.

Country Status (14)

Country Link
US (2) US5457118A (es)
EP (1) EP0579618B1 (es)
JP (1) JP3088015B2 (es)
AT (1) ATE185560T1 (es)
CA (1) CA2104456C (es)
DE (1) DE69230141T2 (es)
DK (1) DK0579618T3 (es)
ES (1) ES2138594T3 (es)
FI (2) FI104070B (es)
GB (1) GB9107043D0 (es)
GR (1) GR3032308T3 (es)
IE (1) IE921060A1 (es)
PT (1) PT100332B (es)
WO (1) WO1992017451A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9220137D0 (en) * 1992-09-23 1992-11-04 Pfizer Ltd Therapeutic agents
AU2044297A (en) * 1996-03-29 1997-10-22 Meiji Seika Kaisha Ltd. Novel heterocyclic compounds having platelet aggregation inhibitory effects
KR20010042125A (ko) * 1998-03-23 2001-05-25 오흘러 로스 제이. 피페리디디닐 및 ｎ-아미디노피페리디닐 유도체
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US6722688B2 (en) 2001-11-21 2004-04-20 The Burton Corporation Snowboard binding system
WO2004050040A2 (en) * 2002-12-03 2004-06-17 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
WO2004069155A2 (en) * 2002-12-03 2004-08-19 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof
US20070032479A1 (en) * 2003-12-03 2007-02-08 Leventer Steven M Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
EP2061761A1 (en) * 2006-09-07 2009-05-27 Millennium Pharmaceuticals, Inc. Phenethylamide derivatives with kinase inhibitory activity
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
CN102316902B (zh) 2009-02-20 2014-09-24 to-BBB控股股份有限公司 基于谷胱甘肽的药物递送系统
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60172964A (ja) * 1984-02-15 1985-09-06 Tanabe Seiyaku Co Ltd 桂皮酸誘導体及びその製法
US4837333A (en) * 1987-05-14 1989-06-06 G. D. Searle & Co. Substituted alkylidene imidazoles
DE3932403A1 (de) * 1989-05-12 1991-04-11 Thomae Gmbh Dr K Neue arylsulfonamide, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IL94805A (en) * 1989-06-28 1994-04-12 Ciba Geigy Ag Certain translocated carboxylic acids (a) Arylsulfonamide - and pyridyl - or imidazolil (), process for their preparation and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
JPH06506200A (ja) 1994-07-14
FI934045A (fi) 1993-09-15
CA2104456C (en) 1996-12-10
FI990179A (fi) 1999-02-01
DE69230141T2 (de) 2000-02-03
FI104070B1 (fi) 1999-11-15
FI934045A0 (fi) 1993-09-15
WO1992017451A1 (en) 1992-10-15
IE921060A1 (en) 1992-10-07
GB9107043D0 (en) 1991-05-22
JP3088015B2 (ja) 2000-09-18
EP0579618B1 (en) 1999-10-13
DE69230141D1 (de) 1999-11-18
PT100332B (pt) 1999-06-30
US5457118A (en) 1995-10-10
CA2104456A1 (en) 1992-10-05
ATE185560T1 (de) 1999-10-15
FI104070B (fi) 1999-11-15
PT100332A (pt) 1993-07-30
GR3032308T3 (en) 2000-04-27
EP0579618A1 (en) 1994-01-26
US5705523A (en) 1998-01-06
DK0579618T3 (da) 2000-01-03
FI990179A0 (fi) 1999-02-01

Similar Documents

Publication Publication Date Title
ES2138594T3 (es) Agentes derivados de piridina e imidazol para enfermedades cardiovasculares.
GB9317764D0 (en) Therapeutic compound
ES2163295T3 (es) Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa.
DE69309670D1 (de) Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
DK0607193T3 (da) Antifugale triazolderivater
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
NZ513594A (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
AR045006A1 (es) Derivados de quinazolinona 5-sustituidos
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
IL182547A0 (en) 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury
SE9904177D0 (sv) Novel compounds
DE60144246D1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
AR027035A1 (es) Pirroles sustituidos
HRP20090617T1 (hr) Protutumorska kombinacija koja sadrži substituirane akriloil distamicinske derivate i protutijela koja inhibiraju čimbenike rasta ili njihove receptore
CO4940439A1 (es) COMPUESTOS 4-AMINO-6,7-DISUSTITUIDOS-PIRIDO-[2,3-d] PIRIMI- DINA
PE20010167A1 (es) Amidas de acidos fenilciclohexanocarboxilicos sustituidos con actividad inhibidora de la incorporacion de adenosina
BRPI0417626A (pt) derivado de 1-[(indol-3-il) carbonil] piperazina tricìclica, composição farmacêutica, uso de um derivado de 1-[(indol-3-il) carbonil] piperazina tricìclica
EP0375451A3 (en) Compounds having a renin-inhibiting activity
ECSP993005A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos
RU2000130705A (ru) Производные индола, лекарственное средство их содержащее, способ их получения (варианты) и применение в качестве ингибитора тирозинкиназы (варианты), применение для лечения опухолевых и других заболеваний (варианты)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 579618

Country of ref document: ES